Back to search resultsSummaryRMgm-63
|
Successful modification | The parasite was generated by the genetic modification |
The mutant contains the following genetic modification(s) | Gene disruption |
Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 16313614 |
MR4 number | |
top of page | |
Parent parasite used to introduce the genetic modification | |
Rodent Malaria Parasite | P. berghei |
Parent strain/line | P. berghei ANKA |
Name parent line/clone | P. berghei ANKA 2.34 |
Other information parent line | |
top of page | |
The mutant parasite was generated by | |
Name PI/Researcher | R. Tewari, C. Doerig, O. Billker |
Name Group/Department | Department of Biological Sciences |
Name Institute | Imperial College |
City | London |
Country | UK |
top of page | |
Name of the mutant parasite | |
RMgm number | RMgm-63 |
Principal name | clone 8.2, clone 8.4 |
Alternative name | Pbmap-2 KO |
Standardized name | |
Is the mutant parasite cloned after genetic modification | Yes |
top of page | |
Phenotype | |
Asexual blood stage | Not different from wild type |
Gametocyte/Gamete | Not different from wild type |
Fertilization and ookinete | Male and female gametocyte production is not affected. Genome replication occurs in the male but no nuclear division/ segmentation. No exflagellation of male gametocytes (no male gamete production). No fertilization since male gametocytes do not produce gametes. |
Oocyst | Not tested |
Sporozoite | Not tested |
Liver stage | Not tested |
Additional remarks phenotype | Mutant/mutation Protein (function) Phenotype See also the paper by Dorin-Semblat D. et al. (2007, Mol Microbiol 65, 1170-1180) for unsuccessful attempts to knock-out map2 in P. falciparum, indicating that in P. falciparum map2 has an essential function during asexual blood stage development. Additional information Other mutants |
top of page | |||||||||||||||||||||||||
Details of the target gene | |||||||||||||||||||||||||
Gene Model of Rodent Parasite | PBANKA_0933700 | ||||||||||||||||||||||||
Gene Model P. falciparum ortholog | PF3D7_1113900 | ||||||||||||||||||||||||
Gene product | mitogen-activated protein kinase 2 | ||||||||||||||||||||||||
Gene product: Alternative name | MAP2; MAP-2; MAPK2 | ||||||||||||||||||||||||
top of page | |||||||||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||||||||
Inducable system used | No | ||||||||||||||||||||||||
Additional remarks inducable system | |||||||||||||||||||||||||
Type of plasmid/construct used | Plasmid double cross-over | ||||||||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||||||||
Plasmid/construct sequence | |||||||||||||||||||||||||
Restriction sites to linearize plasmid | KpnI, ApaI | ||||||||||||||||||||||||
Partial or complete disruption of the gene | Complete | ||||||||||||||||||||||||
Additional remarks partial/complete disruption | |||||||||||||||||||||||||
Selectable marker used to select the mutant parasite | tgdhfr | ||||||||||||||||||||||||
Promoter of the selectable marker | pbdhfr | ||||||||||||||||||||||||
Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||
Selection (negative) procedure | No | ||||||||||||||||||||||||
Additional remarks genetic modification | |||||||||||||||||||||||||
Additional remarks selection procedure | |||||||||||||||||||||||||
Primer information: Primers used for amplification of the target sequences
Primer information: Primers used for amplification of the target sequences
| |||||||||||||||||||||||||
top of page |